Population
Patients with atrial fibrillation (context of drug development)
Design
Review
Authors
Loading...
Novel atrial-selective K+ channel inhibitors for AF remain investigational; leaves open efficacy and safety in randomized trials.
This article reviews the development status of novel atrial-selective K+ channel inhibitors for the treatment of atrial fibrillation.
El-Haou et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: